EULAR definition of difficult-to-treat rheumatoid arthritis

被引:306
作者
Nagy, Gyorgy [1 ,2 ]
Roodenrijs, Nadia M. T. [3 ]
Welsing, Paco M. J. [3 ]
Kedves, Melinda [4 ]
Hamar, Attila [5 ]
van der Goes, Marlies C. [3 ,6 ]
Kent, Alison [7 ]
Bakkers, Margot [8 ]
Blaas, Etienne [3 ]
Senolt, Ladislav [9 ,10 ]
Szekanecz, Zoltan [5 ]
Choy, Ernest [11 ]
Dougados, Maxime [12 ]
Jacobs, Johannes W. G. [3 ]
Geenen, Rinie [13 ]
Bijlsma, Hans W. J. [3 ]
Zink, Angela [14 ,15 ]
Aletaha, Daniel [16 ]
Schoneveld, Leonard [17 ]
van Riel, Piet [18 ]
Gutermann, Loriane [19 ]
Prior, Yeliz [20 ]
Nikiphorou, Elena [21 ]
Ferraccioli, Gianfranco [22 ]
Schett, Georg [23 ,24 ]
Hyrich, Kimme L. [25 ,26 ]
Mueller-Ladner, Ulf [27 ]
Buch, Maya H. [25 ,26 ,28 ]
McInnes, Iain B. [29 ]
van der Heijde, Desiree [30 ]
van Laar, Jacob M. [3 ]
机构
[1] Semmelweis Univ, Dept Rheumatol, Dept Internal Med 3, Budapest, Hungary
[2] Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary
[3] Univ Utrecht, Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands
[4] Bacs Kiskun Cty Hosp, Dept Rheumatol, Kecskemet, Hungary
[5] Univ Debrecen, Fac Med, Dept Rheumatol, Debrecen, Hungary
[6] Meander Med Ctr, Dept Rheumatol, Amersfoort, Netherlands
[7] Salisbury Fdn Trust NHS Hosp, Salisbury, Wilts, England
[8] EULAR Standing Comm People Arthrit Rheumatism Eur, Zurich, Switzerland
[9] Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic
[10] Inst Rheumatol, Prague, Czech Republic
[11] Cardiff Univ, CREATE Ctr, Sch Med, Sect Rheumatol,Div Infect & Immun, Cardiff, Wales
[12] Univ Paris, Hop Cochin, AP HP,Clin Epidemiol & Biostat, Dept Rheumatol,PRES Sorbonne Paris Cite,INSERM,U1, Paris, France
[13] Univ Utrecht, Dept Psychol, Utrecht, Netherlands
[14] Univ Med, Charite, Epidemiol Unit, German Rheumatism Res Ctr, Berlin, Germany
[15] Univ Med, Charite, Rheumatol, Berlin, Germany
[16] Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Vienna, Austria
[17] Bravis Hosp, Dept Rheumatol, Roosendaal, Netherlands
[18] Radboud Univ Nijmegen, Med Ctr, Dept Rheumat Dis, Nijmegen, Netherlands
[19] Paris Descartes Univ, Hop Cochin, AP HP, Dept Pharm, Paris, France
[20] Univ Salford, Ctr Hlth Sci Res, Sch Hlth & Soc, Salford, Lancs, England
[21] Kings Coll London, Ctr Rheumat Dis, London, England
[22] Univ Cattolica Sacro Cuore, Sch Med, Rome, Italy
[23] Friedrich Alexander Univ Erlangen Nuremberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[24] Univ Klinikum Erlangen, Erlangen, Germany
[25] Cent Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
[26] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Ctr Musculoskeletal Res, Manchester, Lancs, England
[27] Justus Liebig Univ Giessen, Kerckhoff Clin Bad Nauhe, Dept Rheumatol & Clin Immunol, Bad Nauheim, Germany
[28] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[29] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[30] Leiden Univ, Dept Rheumatol, Med Ctr, Leiden, Netherlands
关键词
RECOMMENDATIONS;
D O I
10.1136/annrheumdis-2020-217344
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of >= 2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 16 条
  • [1] Biologic interventions for fatigue in rheumatoid arthritis
    Almeida, Celia
    Choy, Ernest H. S.
    Hewlett, Sarah
    Kirwan, John R.
    Cramp, Fiona
    Chalder, Trudie
    Pollock, Jon
    Christensen, Robin
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (06): : CD008334
  • [2] Risk profiling for a refractory course of rheumatoid arthritis
    Becede, Manuel
    Alasti, Farideh
    Gessl, Irina
    Haupt, Lukas
    Kerschbaumer, Andreas
    Landesmann, Uriel
    Loiskandl, Michaela
    Supp, Gabriela M.
    Smolen, Josef S.
    Aletaha, Daniel
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (02) : 211 - 217
  • [3] Defining refractory rheumatoid arthritis
    Buch, Maya H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (07) : 966 - 969
  • [4] Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need
    de Hair, Maria J. H.
    Jacobs, Johannes W. G.
    Schoneveld, Jan L. M.
    van Laar, Jacob M.
    [J]. RHEUMATOLOGY, 2018, 57 (07) : 1135 - 1144
  • [5] Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
    Fautrel, Bruno
    Granger, Benjamin
    Combe, Bernard
    Saraux, Alain
    Guillemin, Francis
    Le Loet, Xavier
    [J]. ARTHRITIS RESEARCH & THERAPY, 2012, 14 (06)
  • [6] Role of Sleep Disturbance, Depression, Obesity, and Physical Inactivity in Fatigue in Rheumatoid Arthritis
    Katz, Patricia
    Margaretten, Mary
    Trupin, Laura
    Schmajuk, Gabriela
    Yazdany, Jinoos
    Yelin, Edward
    [J]. ARTHRITIS CARE & RESEARCH, 2016, 68 (01) : 81 - 90
  • [7] Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
    Kearsley-Fleet, Lianne
    Davies, Rebecca
    De Cock, Diederik
    Watson, Kath D.
    Lunt, Mark
    Buch, Maya H.
    Isaacs, John D.
    Hyrich, Kimme L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (10) : 1405 - 1412
  • [8] Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints:: a comparison with the original DAS remission
    Landewé, R
    van der Heijde, D
    van der Linden, S
    Boers, M
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (05) : 637 - 641
  • [9] PAPADEMETRIOU V, 2011, INT J HYPERTENS, V2011, P1
  • [10] Systematic assessment of difficult-to-treat asthma
    Robinson, DS
    Campbell, DA
    Durharm, SR
    Pfeffer, J
    Barnes, PJ
    Chung, KF
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (03) : 478 - 483